PDAP1

Across TCGA pan-cancer cohorts, PDAP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDAP1 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDAP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDAP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where PDAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.687	0.915	<.001	50	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.261	<.001	26	view →
LUAD	DFS	Median	III,IV	0.886	0.595	.014	11	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
LSCC	DFS	Median	II,III,IV	0.999	0.836	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDAP1–CCRCC (DFS)

Open the CCRCC breakdown →